Literature DB >> 15684648

GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome.

Linda E Pelinka1, Alfred Kroepfl, Martin Leixnering, Walter Buchinger, Andreas Raabe, Heinz Redl.   

Abstract

Research indicates that glial fibrillary acidic protein (GFAP), part of the astroglial skeleton, could be a marker of traumatic brain injury (TBI). S100B, an astroglial protein, is an acknowledged marker of TBI. Our goal was to analyze the relationship of GFAP/S100B to brain damage and outcome, and to compare the accuracy of GFAP/S100B for prediction of mortality after TBI. Our prospective study included 92 patients admitted <12 h after TBI (median injury severity score 25, median Glasgow Coma Scale 6). TBI was verfied by computerized tomography. GFAP/S100B were measured immunoluminometrically at admission and daily in the intensive care unit (average 10 days, range 1-21 days). We compared GFAP/S100B in non-survivors versus survivors, accuracy for mortality prediction according to receiver operated characteristic curve analysis, correlation between GFAP and S100B, relationship of GFAP/S100B to computerized tomography, cerebral perfusion pressure (CPP), mean arterial pressure (MAP) and 3-month Glasgow Outcome Score (GOS). GFAP (p < 0.005) and S100B (p < 0.0005) were higher in non-survivors than survivors. Both GFAP and S100B were accurate for mortality prediction (area under curve 0.84 versus 0.78 at <12 h after TBI). GFAP and S100B release correlated better later than 36 h after TBI (r = 0.75) than earlier (r = 0.58). GFAP was lower in focal lesions of <25 mL than in shifts of >0.5 cm (p < 0.0005) and non-evacuated mass lesions of >25 mL (p < 0.005). S100B was lower in focal lesions of <25 mL than in non-evacuated mass lesions (p < 0.0005) and lower in swelling than in shifts of >0.5 cm (p < 0.005). GFAP and S100B were lower in ICP < 25 than ICP > or = 25 (p < 0.0005), in CPP > or = 60 than CPP < 60 (p < 0.0005), in MAP > 70 than MAP < or = 70 mm Hg, and in GOS 4-5 than GOS 1 (p < 0.0005). Both measurement of GFAP and S100B is a useful non-invasive means of identifying brain damage with some differences based on the pattern of TBI and accompanying multiple trauma and/or shock.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15684648     DOI: 10.1089/neu.2004.21.1553

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  106 in total

1.  Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention.

Authors:  Linda Papa; Lawrence M Lewis; Jay L Falk; Zhiqun Zhang; Salvatore Silvestri; Philip Giordano; Gretchen M Brophy; Jason A Demery; Neha K Dixit; Ian Ferguson; Ming Cheng Liu; Jixiang Mo; Linnet Akinyi; Kara Schmid; Stefania Mondello; Claudia S Robertson; Frank C Tortella; Ronald L Hayes; Kevin K W Wang
Journal:  Ann Emerg Med       Date:  2011-11-08       Impact factor: 5.721

Review 2.  Predictive biomarkers of recovery in traumatic brain injury.

Authors:  Sabrina Giacoppo; Placido Bramanti; Marina Barresi; Debora Celi; Valeria Foti Cuzzola; Eleonora Palella; Silvia Marino
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

Review 3.  Blood-based diagnostics of traumatic brain injuries.

Authors:  Stefania Mondello; Uwe Muller; Andreas Jeromin; Jackson Streeter; Ronald L Hayes; Kevin K W Wang
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

4.  Exacerbated glial response in the aged mouse hippocampus following controlled cortical impact injury.

Authors:  Rajat Sandhir; Gregory Onyszchuk; Nancy E J Berman
Journal:  Exp Neurol       Date:  2008-07-02       Impact factor: 5.330

5.  Depletion of GR-1-Positive Cells Is Associated with Reduced Neutrophil Inflammation and Astrocyte Reactivity after Experimental Intracerebral Hemorrhage.

Authors:  Matthew C Loftspring; Holly L Johnson; Aaron J Johnson; Joseph F Clark
Journal:  Transl Stroke Res       Date:  2012-05-02       Impact factor: 6.829

6.  Protein biomarkers for traumatic and ischemic brain injury: from bench to bedside.

Authors:  Zhiqun Zhang; Stefania Mondello; Firas Kobeissy; Richard Rubenstein; Jackson Streeter; Ronald L Hayes; Kevin K W Wang
Journal:  Transl Stroke Res       Date:  2011-12-07       Impact factor: 6.829

7.  Therapeutic targeting of astrocytes after traumatic brain injury.

Authors:  Jessica Shields; Donald E Kimbler; Walid Radwan; Nathan Yanasak; Sangeetha Sukumari-Ramesh; Krishnan M Dhandapani
Journal:  Transl Stroke Res       Date:  2011-11-09       Impact factor: 6.829

Review 8.  Physiological monitoring of the severe traumatic brain injury patient in the intensive care unit.

Authors:  Peter Le Roux
Journal:  Curr Neurol Neurosci Rep       Date:  2013-03       Impact factor: 5.081

Review 9.  Inflammatory Biomarkers of Birth Asphyxia.

Authors:  Lina F Chalak
Journal:  Clin Perinatol       Date:  2016-09       Impact factor: 3.430

Review 10.  Clinical applications of biomarkers in pediatric traumatic brain injury.

Authors:  Simon J I Sandler; Anthony A Figaji; P David Adelson
Journal:  Childs Nerv Syst       Date:  2009-11-10       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.